Can CGRP Antibodies Treat Medication Overuse Headache Without Forcing Patients to Quit Their Pain Medications Cold Turkey?
CGRP monoclonal antibodies reduced headache days from 30 to 9.5 per month in medication overuse headache patients without requiring abrupt drug discontinuation or hospitalization.
Quick Facts
What This Study Found
After three CGRP-mAb injections, monthly headache days decreased from median 30.0 to 9.5, with 75% of patients achieving ≥50% reduction in headache frequency without abrupt medication discontinuation.
Key Numbers
Data collected at baseline and 1 month after each injection. Multiple outcome measures tracked.
How They Did This
Real-world prospective cohort study of 33 migraine patients with medication overuse headache, measuring outcomes at baseline and after each of three monthly CGRP monoclonal antibody injections.
Why This Research Matters
Medication overuse headache affects millions of migraine patients, and the standard treatment of abrupt drug withdrawal is notoriously difficult to maintain. This approach offers a gentler alternative that may improve compliance and patient quality of life.
The Bigger Picture
CGRP antibodies are transforming migraine treatment, and this study suggests they may also offer a more humane approach to breaking the medication overuse cycle, potentially replacing the painful cold-turkey withdrawal that many patients dread or fail to complete.
What This Study Doesn't Tell Us
Small sample size (33 patients); no control group or comparison with standard abrupt withdrawal; single-center study in Japan; short follow-up of three months; open-label design introduces potential placebo effects.
Questions This Raises
- ?How do outcomes compare directly to the standard abrupt discontinuation approach in a randomized trial?
- ?Do the benefits persist after CGRP antibody treatment is stopped?
- ?Which CGRP antibody (galcanezumab, fremanezumab, erenumab) works best for medication overuse headache specifically?
Trust & Context
- Key Stat:
- 30→9.5 days monthly headache days after three CGRP antibody injections
- Evidence Grade:
- Moderate evidence from a small real-world cohort study without controls. The dramatic effect size is encouraging but requires confirmation in larger, controlled trials.
- Study Age:
- Published in 2024, reflecting current clinical practice with CGRP monoclonal antibodies.
- Original Title:
- Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.
- Published In:
- Heliyon, 10(22), e40190 (2024)
- Authors:
- Tanei, Takafumi(2), Fuse, Yutaro, Maesawa, Satoshi(2), Nishimura, Yusuke, Ishizaki, Tomotaka, Nagashima, Yoshitaka, Mutoh, Manabu, Ito, Yoshiki, Hashida, Miki, Suzuki, Takahiro, Yamamoto, Syun, Wakabayashi, Toshihiko, Saito, Ryuta
- Database ID:
- RPEP-09366
Evidence Hierarchy
Frequently Asked Questions
Do you have to stop all your headache medications at once when using CGRP antibodies for medication overuse headache?
No — this study showed that CGRP antibody injections allowed patients to gradually reduce their medication use without going cold turkey. Monthly headache days still dropped from 30 to under 10.
How quickly do CGRP antibodies help with medication overuse headache?
Improvements began after the first injection, with significant benefits across all measures by the third monthly injection. Headache days dropped by about two-thirds and medication use dropped by over 70%.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09366APA
Tanei, Takafumi; Fuse, Yutaro; Maesawa, Satoshi; Nishimura, Yusuke; Ishizaki, Tomotaka; Nagashima, Yoshitaka; Mutoh, Manabu; Ito, Yoshiki; Hashida, Miki; Suzuki, Takahiro; Yamamoto, Syun; Wakabayashi, Toshihiko; Saito, Ryuta. (2024). Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.. Heliyon, 10(22), e40190. https://doi.org/10.1016/j.heliyon.2024.e40190
MLA
Tanei, Takafumi, et al. "Real-world clinical results of CGRP monoclonal antibody treatment for medication overuse headache of migraine without abrupt drug discontinuation and no hospitalization.." Heliyon, 2024. https://doi.org/10.1016/j.heliyon.2024.e40190
RethinkPeptides
RethinkPeptides Research Database. "Real-world clinical results of CGRP monoclonal antibody trea..." RPEP-09366. Retrieved from https://rethinkpeptides.com/research/tanei-2024-realworld-clinical-results-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.